TrialBMC cancer2020

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.

Cindy Weinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.